Clinical Trials
12 trialsNCT05655598 2024-09-19
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Brown University
Phase 1 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT04054752 2023-11-02
Vaccine Response With NT-I7
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT03552796 2023-06-26
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
University of Southern California
Phase 1 Withdrawn
NCT05259397 2023-03-08
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Pfizer
Phase 1 Withdrawn
NCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT04109092 2020-12-14
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
Eisai Inc.
Phase 1 Withdrawn
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT04089163 2020-03-30
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Tocagen Inc.
Phase 1 Withdrawn
NCT00880854 2019-11-15
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT03007771 2017-10-06
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
Washington University School of Medicine
Phase 1 Withdrawn
NCT00014287 2013-12-19
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
University of Pittsburgh
Phase 1 Withdrawn